A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
1. Abstract 1.1. Introduction: In recent years, many new antidiabetic drugs have been developed. One class of these new antidiabetic drugs are sodium-glucose cotransporter 2 inhibitors (SGLT2i). SGLT2i are associated with an increased risk of euglycemic ketoacidosis (euDKA). Case report: We describe an 81-year-old male with type 2 diabetes mellitus (T2DM), who arrived at the emergency department (ED) after a suspected absence seizure. An arterial blood gas (ABG) demonstrated a high anion gapdoi:10.47829/acmcr.2021.8301 fatcat:ndaed6fiwnactkllhgtxiirizm